Ludwig Cancer Research engages leading scientists and clinicians in an integrated effort to understand and confront the challenge of cancer. The Oxford Branch is based at the University of Oxford, UK and benefits from excellent links with the global Ludwig Cancer Research and local Oxford research communities.
Ludwig Oxford Branch researchers are investigating all stages of cancer, from the risk of disease through to new treatment opportunities. Our research groups are interested in the signalling pathways that influence cancer initiation and progression, with a focus on infection, inflammation and cancer epigenetics. We aim to advance cancer prevention, early diagnosis and effective treatment. Find out more about the Ludwig Oxford research groups.
News
Publications
Parental motivations, facilitators, and barriers to participating in a pediatric vaccine trial in Kathmandu, Nepal: A qualitative study
Journal article
Firth C. et al, (2026), Human Vaccines & Immunotherapeutics, 22
Harnessing prophylactic vaccines for targeted cancer immunotherapy by phage-guided delivery of cognate antigens to tumors
Journal article
Waramit S. et al, (2026), Biomaterials, 334, 124286 - 124286
SorLA regulates B cell receptor uptake, trafficking, and B cell-mediated immune responses in vivo.
Journal article
Berzosa M. et al, (2026), The Journal of experimental medicine, 223
Seminars
Chemical Approaches to Decoding Epigenetics
Thursday, 3 September 2026, 11am to 12pm
Speaker(s): Prof David Xiang
Epigenomic Variation Reveals the Hijacking of Transposable Elements in Cancer
Friday, 4 September 2026, 11am to 12pm
Speaker(s): Dr Mathieu Lupien
conference
